Combination therapies to improve the long-term outcome in hairy cell leukemia

Leukemia and Lymphoma

Volumn 50, Issue SUPPL. 1, 2009, Pages 18-22

  Lauria, Francesco ^a   Forconi, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Combination therapy; Hairy cell leukemia; Outcome; Purine analogs; Rituximab

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CLADRIBINE; FLUDARABINE; IMMUNOTOXIN; IMMUNOTOXIN BL22; MONOCLONAL ANTIBODY; PENTOSTATIN; PURINE DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; HAIRY CELL LEUKEMIA; HUMAN; LONG TERM CARE; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LEUKEMIA, HAIRY CELL; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70449358325     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903142273     Document Type: Review

References (29)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-630.
2. Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Geneve: WHO press, IARC; 2008. p 441.
3. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869-1870.
4. Forconi F, Raspadori D, Lenoci M, et al. Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies. Haematologica 2005;90:266-268.
5. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004;199:59-68.
6. Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol 2008;141:622-630.
7. Forconi F, Sahota SS, Raspadori D, et al. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood 2001;98:1174-1181.
8. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: At the crossroad of somatic mutation and isotype switch. Blood 2004;104: 3312-3317.
9. Tiacci E, Liso A, Piris M, et al. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006;6:437-448.
10. Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15-18.
11. Spiers AS, Parekh SJ. Complete remission in hairy cell leukaemia achieved with pentostatin. Lancet 1984;1:1080-1081.
12. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother 2004;5:1523-1533.
13. Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2- chlorodeoxyadenosine. N Engl J Med 1990;322:1117-1121.
14. Golomb HM. Hairy cell leukemia: Treatment successes in the past 25 years. J Clin Oncol 2008;26:2607-2609.
15. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer 2007;110: 2240-2247.
16. Ravandi F, Jorgensen JL, O'brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-4662.
17. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999;5:1665-1670.
18. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti- CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001;86:1046-1050.
19. Thomas DA, O'brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102: 3906-3911.
20. Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep 2006;8:337-342.
21. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-740.
22. Forconi F, Sozzi E, Raspadori D, et al. Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes. Blood (Suppl) 2006;108:2327(Abstract).
23. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006;8:E532-E551.
24. Forconi F, Toraldo F, Sozzi E, et al. Complete molecular remission induced by concomitant cladribine - rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007;48:2441-2443.
25. Sasaki M, Sugimoto K, Mori T, et al. Effective treatment of a refractory hairy cell leukemia variant with splenic preirradiation and alemtuzumab. Acta Haematol 2008;119:48-53.
26. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: A report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442-2448.
27. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995;13:974-982.
28. Lauria F, Bagnara GP, Catani L, et al. The inhibitory effect of serum from hairy-cell leukaemia patients on normal progenitor cells may disappear following prolonged treatment with alpha-interferon. Br J Haematol 1989;72:497-501.
29. Lauria F, Foa R, Gobbi M, et al. T lymphocyte subsets and colony growth in hairy-cell leukemia. Ric Clin Lab 1982; 12:567-572.